NCT01532102 is a Phase 1, PHASE2 clinical trial of AP611074 in Anogenital Warts, sponsored by Anaconda Pharma.

Who is sponsoring NCT01532102?

NCT01532102 is sponsored by Anaconda Pharma.

What drugs are being tested in NCT01532102?

Interventions in NCT01532102: AP611074, Placebo.

What condition does NCT01532102 study?

NCT01532102 studies Anogenital Warts, Condylomata Acuminata, Human Papillomavirus Infection.

Is NCT01532102 still recruiting?

NCT01532102 is currently completed. Last updated 30 May 2018.

Last reviewed 2018-05-30 · How we verify

NCT01532102

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

Completed Phase 1, PHASE2 Last updated 30 May 2018

What this trial tests

Phase 1, PHASE2 trial testing AP611074 in Anogenital Warts in 24 participants. Completed in 6 May 2013.

Timeline

28 February 2012

Primary endpoint
6 May 2013

6 May 2013

Quick facts

Lead sponsor	Anaconda Pharma
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	24
Start date	28 February 2012
Primary completion	6 May 2013
Estimated completion	6 May 2013
Sites	4 locations across France, Argentina

Drugs / interventions tested

AP611074 — full drug profile →
Placebo

Conditions studied

Anogenital Warts — all drugs for Anogenital Warts →
Condylomata Acuminata — all drugs for Condylomata Acuminata →
Human Papillomavirus Infection — all drugs for Human Papillomavirus Infection →

Sponsor

Anaconda Pharma — full company profile →

Who can join

Adults 18 to 55, any sex, with Anogenital Warts or Condylomata Acuminata. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the safety, tolerability and efficacy of the topical application of AP611074 5% gel during 6 weeks on ano-genital warts caused by human papillomavirus (HPV).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond.
Chaudhuri S, Symons JA, Deval J. · · 2018 · cited 136× · PMID 29758235 · DOI 10.1016/j.antiviral.2018.05.005

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01532102 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anaconda Pharma
Last refreshed: 30 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01532102.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing